On September 23, 2026, Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQ: VNDA) with an “Outperform” recommendation. The stock closed at $5.21 on September 22, reflecting a one-week price increase of 4.41% from $4.99 on September 15, 2026.
The current consensus target price for Vanda Pharmaceuticals is set at $12.43, suggesting a potential upside of 138.60%. As of September 1, 2026, there are 10 recommendations for the stock: 2 strong buy, 6 buy, and 2 hold, indicating an 80% positive outlook.
Vanda Pharmaceuticals reported an earnings per share (EPS) of -1.04 on August 5, 2026, missing the estimated EPS of -0.5993, with actual revenue of $50.53 million, below the expected $63.16 million.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
